A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

410

Enrollment

INDUSTRY

Sponsor class

Conditions

Psychosis Associated With Alzheimer's Disease

Interventions

DRUG: KarXT
DRUG: Placebo

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company